ABS Biotechnologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ABS Biotechnologies is a private, pre-revenue platform company based in Vienna, Austria, specializing in predictive human cell-based assays for drug safety screening. Its core technology utilizes differentiated stem cells to produce highly functional blood vessel cells and cardiomyocytes, enabling more accurate identification of cardiovascular toxicities early in drug development. The company targets the pharmaceutical and biotechnology sectors as partners, offering a service-based platform to de-risk R&D pipelines. ABS appears to be in a pre-clinical or discovery stage, building its team and technology to capture a niche in the growing preclinical safety assessment market.

Cardiovascular Safety

Technology Platform

Next-generation stem cell differentiation platform producing high-maturity human blood vessel cells and cardiomyocytes for predictive drug safety screening.

Opportunities

Growing demand for human-relevant models to reduce animal testing and improve drug safety prediction creates a large addressable market.

The high cost of late-stage clinical failures due to cardiovascular toxicity provides a strong value proposition for a predictive platform.

Regulatory trends are increasingly supportive of novel, human-based assay systems.

Risk Factors

The business depends entirely on validating that its cell models are superior to existing screening methods.

As a pre-revenue startup, it faces significant financial risk and reliance on external funding.

It must overcome market adoption barriers in a competitive preclinical services landscape.

Competitive Landscape

ABS competes with other stem cell-based assay providers (e.g., Ncardia, Axol Bioscience), larger CROs offering standard toxicology services, and in-house capabilities at pharmaceutical companies. Its differentiation hinges on the claimed superior maturity and functionality of its specific cardiovascular cell types.

More companies in Diagnostics & Precision Medicine →More companies in Austria →